Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H W
Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Str 40, D-60596, Frankfurt, Germany.
Lancet. 2003 Jun 14;361(9374):2045-6. doi: 10.1016/s0140-6736(03)13615-x.
The outbreak of SARS warrants the search for antiviral compounds to treat the disease. At present, no specific treatment has been identified for SARS-associated coronavirus infection. We assessed the antiviral potential of ribavirin, 6-azauridine, pyrazofurin, mycophenolic acid, and glycyrrhizin against two clinical isolates of coronavirus (FFM-1 and FFM-2) from patients with SARS admitted to the clinical centre of Frankfurt University, Germany. Of all the compounds, glycyrrhizin was the most active in inhibiting replication of the SARS-associated virus. Our findings suggest that glycyrrhizin should be assessed for treatment of SARS.
严重急性呼吸综合征(SARS)的爆发促使人们寻找抗病毒化合物来治疗该疾病。目前,尚未确定针对SARS相关冠状病毒感染的特异性治疗方法。我们评估了利巴韦林、6-氮杂尿苷、吡唑呋林、霉酚酸和甘草甜素对从德国法兰克福大学临床中心收治的SARS患者中分离出的两株冠状病毒(FFM-1和FFM-2)的抗病毒潜力。在所有这些化合物中,甘草甜素在抑制SARS相关病毒复制方面活性最强。我们的研究结果表明,应评估甘草甜素对SARS的治疗作用。